Clinical Management, Monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan

Antibody –drug conjugates (ADCs) are directed therapies that are designed to increase efficacy and decrease toxicity compared with conventional chemotherapy through the selective delivery of cytotoxic agents to tumor cells [1,2]. ADCs that have been approved as anti-cancer agents in various solid tumors in clude trastuzumab emtansine (T-DM1), trastuzumab deruxtecan (T-DXd), sacituzumab govitecan, mirvetuximab soravtansine, and tisotumab vedotin [3–7]. However, some patients have experienced adverse events (AEs) that require prevention, early recognition, and appropriate management [3–7].

Source: Cancer Treatment Reviews - March 11, 2024 Category: Cancer & Oncology Authors: Rebecca S. Heist, Jacob Sands, Aditya Bardia, Toshio Shimizu, Aaron Lisberg, Ian Krop, Noboru Yamamoto, Takahiro Kogawa, Saba Al-Hashimi, Simon S.M. Fung, Anat Galor, Francesca Pisetzky, Priyanka Basak, Cindy Lau, Funda Meric-Bernstam Source Type: research